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Structure–Activity Relationship Studies on (R)-PFI-2
Analogues as Inhibitors of Histone Lysine
Methyltransferase SETD7
Danny C. Lenstra,[a] Eddy Damen,[b] Ruben G. G. Leenders,[b] Richard H. Blaauw,[c]
Floris P. J. T. Rutjes,[a] Anita Wegert,[b] and Jasmin Mecinovic´*[a]
Introduction
Covalent posttranslational modifications on the unstructured
N-terminal histone tails play an important role in regulating
the activity of human genes.[1] These modifications are intro-
duced by ‘writers’ and, among others, include methylation,
acetylation, phosphorylation, citrullination, and ubiquitina-
tion.[2] Methylation is one of the most abundant and well-stud-
ied modifications on histones.[3] The transfer of a methyl group
from co-substrate S-adenosylmethionine (SAM) to lysine resi-
dues is catalyzed by histone lysine methyltransferases (KMTs).[4]
KMTs can catalyze the addition of up to three methyl groups
to the e-amino group of lysine residues, affording methyllysine
(Kme), dimethyllysine (Kme2) and trimethyllysine (Kme3).[5]
With the exception of DOT1L, an H3K79 methyltransferase, all
KMTs contain a highly conserved SET (Su(var)3–9, enchanter-of-
zeste, thritorax) domain, which is responsible for their catalytic
activity.[6]
SET domain containing lysine methyltransferase 7 (SETD7,
also known as SET7/9) was originally identified as a monome-
thylase of lysine 4 on histone 3 (H3K4).[7] Unlike many other
methyltransferases, SETD7 only monomethylates H3K4, but
does not catalyze di- or trimethylation of lysine. This methyla-
tion mark (H3K4me) has a functional effect on the chromatin
state resulting in activation of transcription. SETD7 has also
been found to catalyze methylation of a range of non-histone
proteins, including estrogen receptor a (ERa),[8] DNA methyl-
transferases 1 (DNMT1),[9] TAF10,[10] FoxO3,[11] transcription fac-
tors YY1 and Pdx1,[12] androgen receptor,[13] ARTD1,[14] b-cate-
nin,[15] and tumor suppressor p53.[16] Recent biomedical studies
revealed that SETD7 is involved in multiple signaling pathways,
and its aberrant activity has been linked to various types of
cancer[17] and vascular dysfunction in patients with type 2 dia-
betes.[18] The development of SETD7 small molecule inhibitors
as chemical probes for studying their biological activity in cells
is therefore highly desired and may lead to the development
of therapeutic agents for the treatment of human diseas-
es.[18,19]
To date, only a few selective SETD7 inhibitors have been
identified. Clinically approved antihistaminic cyproheptadine
was found to inhibit SETD7-mediated methylation of H3K4
(IC50 of 3.4 mm). The substrate in this study was ERa, and in
vivo inhibition led to blocking of estrogen-dependent breast
cancer cell growth in MCF7 cells.[20] A structure–activity rela-
tionship study was performed, however, none of the analogues
proved to be more potent than cyproheptadine.[21] Several
SAM derivatives have also been reported to inhibit SETD7
methyltransferase activity; for instance, DAAM-3 (IC50 10 mm)
[22]
and DC-S239 (IC50 4.59 mm).
[23] Unfortunately, SAM-competitive
inhibitors usually have poor selectivity amongst other methyl-
transferases due to the highly conserved SAM binding domain
in the methyltransferase family. The most potent known SETD7
inhibitor (IC50=2.0:0.2 nm) is (R)-PFI-2 (Figure 1b–c), while its
enantiomer (S)-PFI-2 proved to be a very weak SETD7 inhibitor,
highlighting that the stereochemistry of the amino acid side
chain defines its potency.[24] (R)-PFI-2 is a histone competitive
inhibitor, and exhibits an inhibition potency in vitro and in cel-
lular assays.[24] Comparative studies demonstrated that (R)-PFI-2
is selective for SETD7 over 18 other human methyltransferases.
SETD7 is a histone H3K4 lysine methyltransferase involved in
human gene regulation. Aberrant expression of SETD7 has
been associated with various diseases, including cancer. There-
fore, SETD7 is considered a good target for the development
of new epigenetic drugs. To date, few selective small-molecule
inhibitors have been reported that target SETD7, the most
potent being (R)-PFI-2. Herein we report structure–activity rela-
tionship studies on (R)-PFI-2 and its analogues. A library of 29
structural analogues of (R)-PFI-2 was synthesized and evaluated
for inhibition of recombinantly expressed human SETD7. The
key interactions were found to be a salt bridge and a hydro-
gen bond formed between (R)-PFI-2’s NH2
+ group and SETD7’s
Asp256 and His252 residue, respectively.
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Although the structure of (R)-PFI-2 in complex with SETD7 has
been solved (Figure 1b), no further analogues have been re-
ported. To investigate which structural elements of (R)-PFI-2
are essential for effective inhibition of SETD7, we carried out a
structure–activity relationship (SAR) study. We modified three
distinctive moieties that have a potential to crucially contribute
to the potency of (R)-PFI-2: 1) The amino acid side chain (Fig-
ure 1c, part A); 2) the pyrrolidine amide (Figure 1c, part B);
and 3) the tetrahydroisoquinoline moiety (Figure 1c, part C).
Results and Discussion
We initiated our investigations with the synthesis of (R)-PFI-2
(1) and its 29 structural analogues (Scheme 1). In general, the
synthesis was adapted from a published protocol,[24] and starts
from an unnatural d-amino acid; typically Boc-protected d-
phenylalanine derivatives were coupled to the requisite
amines using EDCI, HOBt, and DIPEA. Then the Boc group was
removed with TFA in CH2Cl2, followed by a basic workup to
afford the free amine. The sulfonyl part of the inhibitor was
synthesized from various aryl bromides (Scheme 1). These aryl
bromides were first reacted with benzyl mercaptan in the pres-
ence of Pd2(dba)3 and Xantphos to afford aryl benzyl sulfides,
followed by oxidation with trichloroisocyanuric acid to yield
the corresponding sulfonyl chlorides. The sulfonyl chlorides
were then coupled to the free amines in the presence of trie-
thylamine in CH2Cl2 to afford the desired structural analogues
of (R)-PFI-2.
Initially, all synthesized compounds were tested for their in-
hibitory activity using an established matrix-assisted laser de-
sorption-ionization time-of-flight mass spectrometry (MALDI-
TOF MS) assay, monitoring the monomethylation of a synthetic
21-mer histone 3 peptide mimic containing a lysine at posi-
tion 4.[25] In a typical assay, 200 nm of SETD7, 10 mm of H3K4
histone peptide, 16 mm of SAM and 10 or 100 mm of com-
pounds 1–30 were incubated for 1 hour at 37 8C. For com-
pounds showing >50% inhibition at 100 mm, IC50 values were
determined. In cases where <50% inhibition at 100 mm was
observed, IC50 values were not determined and this data is pre-
sented as IC50>100 mm. Enzymatic activity of these com-
pounds at 100 mm concentration can be found in Figure S1 in
the Supporting Information (SI). Representative MALDI data of
selected compounds at 10 mm are shown in Figure 2. In a con-
trol experiment without inhibitor (5% (v/v) of DMSO) nearly
quantitative methylation was observed in the presence of
human SETD7 (m/z=2269.5) (Figure 2a). Under standard con-
ditions, but in the presence of 10 mm of (R)-PFI-2 (compound
1), no methylation was observed in the MALDI spectrum (Fig-
ure 2b).
We further examined the potency of (R)-PFI-2 against recom-
binantly expressed human SETD7. Under our assay conditions,
an IC50 value of 138 nm was obtained for (R)-PFI-2 (Figure 3,
compound 1), indicating very effective inhibition of SETD7
methyltransferase activity. Previously reported IC50 values for
(R)-PFI-2 were 2.0 and 55 nm, respectively;[24,25b] the observed
difference with our measured IC50 value is due to differences in
employed assay and assay conditions. Representative inhibi-
tion curves can be found in SI Figure S2. Two isomers of 1,
with ortho- (compound 2) and para-CF3 (compound 3) sub-
stituents also displayed excellent inhibitory activity with IC50
values of 203 and 173 nm, respectively. The potencies of ana-
Figure 1. a) SETD7-catalyzed methylation of H3K4; b) crystal structure of
SETD7 (grey) in complex with (R)-PFI-2 (cyan) (PDB ID: 4JLG) ; c) structure of
(R)-PFI-2, with sites A, B, and C for SAR exploration.
Scheme 1. Syntheses of (R)-PFI-2 and its analogues 1–28 : i) Boc2O, NaOH in
H2O/dioxane (1:1 v/v), RT, 20 h; ii) EDCI, HOBt, DIPEA, R2NH in CH2Cl2, RT,
20 h; iii) TFA/CH2Cl2 (1:1 v/v), RT, 2–4 h; iv) Pd2(dba)3, Xantphos, DIPEA, ben-
zylmercaptan in dioxane, 100 8C, 6 h; v) benzyltrimethylammonium chloride,
trichloroisocyanuric acid, Na2CO3 in H2O/MeCN, 0 8C!RT, 1 h; vi) Et3N in
CH2Cl2, RT, 4 h. Where applicable, Boc-protected compounds were deprotect-
ed using TFA/CH2Cl2 (1:1 v/v).
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logues 4–6 bearing a methyl, chloro, or bromo functionality at
the meta-position were evaluated next. All compounds were
found to be excellent inhibitors of SETD7 with IC50 values rang-
ing from 132 to 178 nm. Also compound 7, which does not
contain any substituent on the phenyl ring, was found to be a
good SETD7 inhibitor with an IC50 of 266 nm. Adding an extra
fused ring, as in the naphthalene-containing compound 8,
gave an IC50 of 145 nm, indicating that there is sufficient space
available for additional functionalization. Notably, removing
the entire side chain (as in glycine-based compound 9) led to
rather poor inhibition with an IC50 of 79 mm, implying that the
aromatic ring is crucial for potency.
Next, the effect of modifications in the pyrrolidine amide
side chain was investigated (Figure 1c, part B). The analysis of
the crystal structure of (R)-PFI-2 as co-crystal with SETD7 and
SAM (PDB ID: 4JLG) illustrates that the pyrrolidine part of the
inhibitor is positioned inside the lysine channel pointing to-
wards SAM (Figure 1b). Based on this structural information, it
is clear that space in this pocket is limited and that a signifi-
cant increase in the size of the pyrrolidine moiety would pre-
sumably not be tolerated. Indeed, 1-adamantyl-substituted
compound 10 did not show any inhibitory activity against
SETD7. No significant difference in IC50 was observed when the
five-membered ring of the pyrrolidine amide (compound 7,
266 nm) was replaced by a four-membered ring: an IC50 of
290 nm was obtained for azetidine derived analogue 11. By
slightly increasing the ring size to piperidine or morpholine
amide, as in analogues 12 and 13, IC50 values of 1.3 and
1.9 mm were observed, respectively. This result shows that a
slight increase in ring size from five- to six-membered already
leads to an approximate fivefold decrease in potency (com-
pound 7 versus 12). Replacement of the five-membered ring
with acyclic diethylamine derivative 14 resulted in a higher
degree of rotational freedom, which could lead to a steric
clash with SETD7’s pocket; this proposition is in line with a sur-
prisingly higher IC50 value of 20 mm. An almost 10-fold lower
IC50 of 2.6 mm was obtained by decreasing the size and rota-
tional freedom in dimethylamine derivative 15. Removal of the
entire pyrrolidine amide side chain (as in compound 16), re-
sulted in the formation of an achiral compound. This signifi-
cant structural change caused that 16 is no longer an inhibitor
of SETD7 within limits of detection.
Finally, the importance of the tetrahydroisoquinoline rings
was investigated (Figure 1c, part C). The simplest analogues
17–19, consisting of a phenyl ring, either unsubstituted or
with fluorine on the meta or para position, did not significantly
inhibit SETD7 methyltransferase activity, indicating the essen-
tial role of the tetrahydroisoquinoline scaffold of (R)-PFI-2 in in-
hibition of SETD7. IC50 values of >100 mm were observed for
several heteroatom-substituted analogues 20–22, containing
for instance a planar or nonplanar heterocyclic system. To in-
vestigate the importance of the fluorine substituent, we syn-
thesized analogue 23, which has an IC50 value of 532 nm ; this
is an approximate twofold increase with respect to fluorine-
containing compound 7 (IC50=266 nm). Approximately 10%
inhibition of methyltransferase activity was observed in the
presence of 100 mm of compound 24, an analogue of 7 that
has the positively charged quaternary ammonium group
(under physiological conditions) replaced by a neutral methyl-
ene group of equal size (SI Figure S1). This result demonstrates
that the positively charged NH2
+ of (R)-PFI-2 is involved in two
interactions with SETD7, namely as a salt bridge with Asp256
and a hydrogen bond with His252. Notably, when this nitrogen
was translocated one position, as in tetrahydroquinoline 25,
again no inhibition was observed, whereas for compound 26,
only a poor inhibition with an IC50 value of 20 mm was ob-
served. Based on our examination of compounds 23–26, it is
clearly evident that the most important contributor to the ex-
cellent potency of (R)-PFI-2 is the nitrogen-containing tetrahy-
droisoquinoline functionality. Having a benzylamine moiety in-
stead of the cyclic structure, as in compound 27, a moderately
active compound is obtained (IC50=2.7 mm). With compound
28, a formation of a salt bridge is no longer possible after
changing the free amine to an amide functionality, and conse-
quently no inhibition was observed. The two individual frag-
ments of which the (R)-PFI-2 scaffold consists also showed no
inhibitory activity (Figure 3, compounds 29 and 30).
Docking studies were then carried out to obtain more de-
tailed information about the potential binding modes of vari-
ous (R)-PFI-2 analogues (Figure 4a–f). Initially, to confirm the
correct docking mode, (R)-PFI-2 was successfully redocked into
the structure of SETD7 (RMSD=0.638 a, Figure 4a). The ligand
interaction diagram for SETD7-(R)-PFI-2 is shown in SI Fig-
ure S3. Compound 8 was docked into SETD7 and the binding
mode of 8 was found to be similar to that of (R)-PFI-2 (Fig-
ure 4b). In the docked structure of 12, the piperidine group
occupies the narrow lysine binding channel; although it is
somewhat larger than (R)-PFI-2’s pyrrolidine group, 12 does
not noticeably clash with the protein (Figure 4c). Finally, two
structures with the tetrahydroisoquinoline core were docked.
Despite being a very poor inhibitor of SETD7 (10% inhibition
at 100 mm, SI Figure S1), docking of the carbon analogue 24
was successful and the apparent binding mode seems similar
Figure 2. a) Representative MALDI-TOF MS data for 200 nm SETD7, 21-mer
H3K4 peptide (10 mm), SAM (16 mm) in 50 mm glycine pH 8.8 containing
2.5% glycerol and 5% DMSO (v/v) after 1 h at 37 8C; b) 10 mm (R)-PFI-2 (com-
pound 1) ; c) 10 mm compound 9 ; d) 10 mm compound 14 ; e) 10 mm com-
pound 27. Y-axes: relative abundance.
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to that of (R)-PFI-2, in spite of the absence of interactions with
Asp256 and His252 (Figure 4d). In contrast, the benzylamine-
derived compound 27 does have a potential to form a salt
bridge with Asp256 and a hydrogen bond with His252 under
physiological conditions, and docking of this molecule into
SETD7 confirmed the existence of the energetically favorable
salt bridge and hydrogen bond (Figure 4e).
Conclusions
A library of 29 (R)-PFI-2 analogues was synthesized and evalu-
ated as SETD7 inhibitors with the aim to determine which
structural features contribute to the excellent potency of (R)-
PFI-2. Our results demonstrate that small perturbations in the
pyrrolidine amide side chain, that is, piperidine amide 12 or di-
methylamide 15 were tolerated relatively well, whereas sub-
stituents with more rotational freedom (e.g. , diethylamide 14)
Figure 3. A library of (R)-PFI-2 (compound 1) and its analogues 2–30, showing half-maximum inhibitory concentrations (IC50 values).
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or with increased size (e.g. , adamantane 10) were not tolerat-
ed. Substitutions on the aromatic side chain led to highly
potent (R)-PFI-2 analogues. The key interactions between
SETD7 and (R)-PFI-2 were identified to be a salt bridge and a
hydrogen bond that are formed between SETD7’sAsp256/
His252 and the tetrahydroisoquinoline’s NH2
+ group of (R)-PFI-
2. Removal or repositioning of this ammonium group resulted
in analogues that were inactive (compounds 24 and 25) or
only poorly active (compound 26), whereas a replacement of
the tetrahydroisoquinoline moiety by benzylamine (as in com-
pound 27) resulted in a &10-fold less potent inhibitor. It is en-
visioned that this study will importantly contribute to the
growing field of epigenetic drug discovery.
Experimental Section
Inhibition studies : For determination of IC50 values, a MALDI-TOF-
MS-based assay monitoring methylation of a 21-mer histone 3 pep-
tide mimic containing a lysine at position 4 was used. Briefly,
SETD7 (200 nm final concentration) was pre-incubated with com-
pound (100% DMSO stock solution at appropriate concentration)
for 5 min at 37 8C in 18 mL of 50 mm glycine pH 8.8 containing
2.5% glycerol as assay buffer. Then, 2 mL of SAM (16 mm final con-
centration) and 21-mer H3K4 peptide (10 mm final concentration)
premixture was added to initiate the enzymatic reaction, thereby
obtaining a final reaction volume of 20 mL containing 5% DMSO
(v/v). The reaction was left to incubate for an additional 1 h at
37 8C after which it was quenched by the addition of 20 mL of
methanol. For MALDI-TOF MS analysis, a 2 mL aliquot from the
quenched reaction mixture was mixed with 8 mL of saturated
HCCA matrix (a-cyano-4-hydroxycinnamic acid, Sigma–Aldrich).
From this mixture 1 mL was deposited on the MALDI plate for crys-
tallization. Methyltransferase activity was calculated by taking the
peak area of monomethylation state (including all isotopes and ad-
ducts), and is expressed relative to the reaction in which no com-
pound was present (control experiment in which just 5% DMSO
was present). The calculated activities were plotted against the cor-
responding compound concentrations and fitted to the Hill equa-
tion using OriginPro 2017 SR2 software (version b9.4.2.380). Each
experiment was performed in triplicate.
Docking studies : The crystal structure of SETD7 in complex with
(R)-PFI-2 and S-adenosylmethionine (SAM)[24] was downloaded from
the RCSB Protein Data Bank (PDB ID: 4JLG). The protein–ligand
complex (chain A) was prepared for docking using the QuickPrep
wizard in Molecular Operating Environment (MOE).[26] All com-
pounds to be docked were prepared using the default settings of
the Wash wizard as implemented in MOE. Molecular docking was
performed using Molegro Virtual Docker v6.0.[27] The active binding
site region was defined as a spherical region, which encompasses
all protein within 10.0 a of bound (R)-PFI-2. Both the MolDock
Score [GRID] and PLANTS Score [GRID] with a grid resolution of
0.2 a were evaluated to score and rank the five best docking poses
for each compound. MolDock SE was selected as search algorithm
Figure 4. Docking studies on various (R)-PFI-2 analogues (cyan) with SETD7 (cartoon, grey) with SAM (grey). SETD7 residues that form key interactions are
shown in purple : a) Redocked structure of (R)-PFI-2 (compound 1), RMSD=0.638; b) docking of compound 8, containing a naphthalene side chain; c) docking
of compound 12, containing a piperidine amide functionality; d) docking of carbon analogue 24 ; e) docking of benzylamine-type compound 27; f) superim-
position of structures shown in panels a–e, with SETD7 surface visualization (grey).
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using its default settings. All figures were prepared with PyMOL
visualization software.[28]
Characterization of final compounds : Compound 1 (25 mg, 75%
isolated yield, off-white solid): 1H NMR (400 MHz, CDCl3): d=7.51–
7.46 (m, 1H), 7.40–7.35 (m, 2H), 7.33–7.31 (m, 2H), 7.19 (d, J=8.7,
1H), 4.19 (t, J=7.5, 1H), 4.03 (bs, 2H), 3.22–3.06 (m, 5H), 2.99 (d,
J=7.5, 2H), 2.86–2.75 (m, 2H), 2.59–2.47 (m, 1H), 1.76–1.52 (m,
4H), 1.25 ppm (bs, 1H); 13C NMR (101 MHz, CDCl3): d=168.3, 160.0,
157.5, 139.0, 138.9, 138.8, 138.7, 136.7, 133.0, 133.0, 131.3, 131.0,
130.7, 130.3, 129.0, 128.5, 128.3, 126.1, 126.1, 126.0, 126.0, 125.2,
124.1, 124.0, 124.0, 123.9, 123.4, 123.3, 122.5, 111.0, 110.8, 110.0,
55.8, 46.2, 45.8, 42.6, 42.1, 42.1, 39.9, 28.8, 28.8, 25.7, 23.8 ppm;
19F NMR (377 MHz, CDCl3): d=@62.6, @116.9 ppm; MS (ESI) m/z
500.0 [M+H]+ ; HRMS (ESI) found m/z 500.16332 [M+H]+ , calcd
for C23H26F4N3O3S
+ m/z 500.16310; ½aA21D =@73.28 (CH2Cl2).
Compound 2 (31 mg, 83% isolated yield, white solid): 1H NMR
(400 MHz, CDCl3): d=7.53–7.48 (m, 2H), 7.33 (bs, 1H), 7.28–7.24
(m, 3H), 7.20 (dd, J=1.7, 8.7 Hz, 1H), 4.20 (t, J=7.3 Hz, 1H), 4.02 (s,
2H), 3.24–3.06 (m, 5H), 2.99 (d, J=7.3 Hz, 2H), 2.88–2.70 (m, 2H),
2.67–2.56 (m, 1H), 1.79–1.52 (m, 4H), 1.26 ppm (bs, 1H); 13C NMR
(101 MHz, CDCl3): d=168.1, 160.0, 157.5, 139.8, 139.8, 139.8, 139.8,
139.0, 138.9, 138.8, 138.7, 129.9, 129.7, 129.4, 128.9, 128.7, 125.4,
125.3, 125.3, 125.3, 123.4, 123.4, 122.7, 111.0, 110.7, 55.7, 46.2, 45.8,
42.8, 42.4, 42.3, 39.9, 29.0, 29.0, 25.7, 23.9 ppm; 19F NMR (377 MHz,
CDCl3): d=@62.53, @117.11 ppm; MS (ESI) m/z 500.1 [M+H]+ ;
HRMS (ESI) found m/z 500.16353 [M+H]+ , calcd for C23H26F4N3O3S
+
m/z 500.16310; ½aA21D =@91.38 (CH2Cl2).
Compound 3 (35 mg, 91% isolated yield, off-white solid): 1H NMR
(400 MHz, CDCl3): d=7.58 (d, J=7.7 Hz, 1H), 7.43–7.28 (m, 4H),
7.18–7.13 (m, 1H), 4.30 (t, J=7.7 Hz, 1H), 4.02 (s, 2H), 3.23 (t, J=
6.3 Hz, 3H), 3.18–3.00 (m, 4H), 2.84–2.73 (m, 2H), 2.68–2.61 (m,
1H), 1.81–1.57 (m, 4H), 1.24 ppm (bs, 1H); 13C NMR (101 MHz,
CDCl3): d=168.7, 160.0, 157.5, 139.0, 138.9, 138.7, 138.7, 134.1,
133.3, 133.2, 131.6, 129.0, 128.7, 128.6, 128.5, 127.3, 126.0, 125.9,
125.8, 123.4, 123.4, 123.1, 111.0, 110.8, 55.2, 46.0, 45.9, 42.8, 42.4,
42.4, 36.7, 30.9, 29.0, 25.8, 23.9 ppm; 19F NMR (377 MHz, CDCl3): d=
@62.6, @117.1 ppm; MS (ESI) m/z 500.1 [M+H]+ ; HRMS (ESI) found
m/z 500.16319 [M+H]+ , calcd for C23H26F4N3O3S
+ m/z 500.16310;
½aA21D =@74.08 (CH2Cl2).
Compound 4 (47 mg, 69% isolated yield, off-white solid): 1H NMR
(400 MHz, CDCl3): d=7.34–7.31 (m, 1H), 7.20 (dd, J=1.8, 8.8 Hz,
1H), 7.11 (t, J=7.9 Hz, 1H), 7.03–6.98 (m, 1H), 6.94–6.88 (m, 2H),
4.16 (dd, J=6.7, 8.5 Hz, 1H), 4.03 (bs, 2H), 3.22–3.01 (m, 5H), 2.94–
2.73 (m, 4H), 2.49–2.38 (m, 1H), 2.27 (s, 3H), 1.71–1.45 (m, 4H),
1.26 ppm (bs, 1H); 13C NMR (101 MHz, CDCl3): d=168.7, 160.0,
157.5, 139.1, 139.1, 138.7, 138.6, 138.0, 135.5, 130.1, 128.4, 128.3,
128.2, 127.8, 126.4, 123.4, 123.4, 111.1, 110.8, 56.2, 46.1, 45.7, 42.7,
42.2, 42.2, 40.4, 28.9, 25.7, 23.9, 21.3 ppm; 19F NMR (377 MHz,
CDCl3): d=@117.2 ppm; MS (ESI) m/z 446.1 [M+H]+ ; HRMS (ESI)
found m/z 446.19004 [M+H]+ , calcd for C23H29FN3O3S
+ m/z
446.19006; ½aA21D =@91.18 (CH2Cl2).
Compound 5 (14 mg, 81% isolated yield, off-white solid): 1H NMR
(400 MHz, CDCl3): d=7.32–7.29 (bs, 1H), 7.22–7.14 (m, 3H), 7.08–
7.00 (m, 2H), 4.19–4.13 (t, J=7.4 Hz, 1H), 4.02 (s, 2H), 3.28–3.09 (m,
5H), 2.91 (d, J=7.4 Hz, 2H), 2.85–2.76 (q, J=6.1 Hz, 2H), 2.66–2.56
(m, 1H), 1.79–1.58 (m, 4H), 1.26 ppm (bs, 1H); 13C NMR (126 MHz,
CDCl3): d=168.4, 159.8, 157.8, 138.8, 138.8, 138.8, 137.7, 134.2,
129.7, 129.4, 128.6, 128.5, 127.7, 127.3, 123.4, 123.4, 111.0, 110.8,
55.9, 46.2, 45.9, 42.8, 42.3, 42.3, 39.9, 28.9, 28.9, 25.8, 23.9 ppm;
19F NMR (377 MHz, CDCl3): d=@117.0 ppm; MS (ESI) m/z 466.1
[M+H]+ ; HRMS (ESI) found m/z 466.13652 [M+H]+ , calcd for
C22H26ClFN3O3S
+ m/z 466.13674; ½aA21D =@88.98 (CH2Cl2).
Compound 6 (18 mg, 72% isolated yield, off-white solid): 1H NMR
(400 MHz, CDCl3): d=7.35–7.29 (m, 2H), 7.24–7.16 (m, 2H), 7.14–
7.06 (m, 2H), 4.16 (t, J=7.5 Hz, 1H), 4.05 (s, 2H), 3.28–3.10 (m, 5H),
2.88 (d, J=7.5 Hz, 2H), 2.85–2.78 (m, 2H), 2.66–2.55 (m, 1H), 1.79–
1.58 (m, 4H) 1.26 ppm (bs, 1H); 13C NMR (126 MHz, CDCl3): d=
168.4, 159.7, 157.8, 138.9, 138.9, 138.7, 138.6, 138.0, 132.3, 130.2,
130.0, 128.8, 128.3, 128.2, 128.2, 123.3, 123.3, 122.4, 111.0, 110.8,
55.9, 46.2, 45.9, 42.7, 42.2, 42.2, 39.8, 39.7, 29.7, 29.3, 28.7, 25.8,
23.9 ppm; 19F NMR (377 MHz, CDCl3): d=@117.1 ppm; MS (ESI) m/z
511.9 [M+H]+ ; HRMS (ESI) found m/z 510.08574 [M+H]+ , calcd for
C22H26BrFN3O3S
+ m/z 510.08523; ½aA21D =@50.88 (CH2Cl2).
Compound 7 (13 mg, 64% isolated yield, white solid): 1H NMR
(500 MHz, CDCl3): d=7.33 (bs, 1H), 7.25–7.18 (m, 4H), 7.14–7.09
(m, 2H), 4.16 (dd, J=8.9, 6.2 Hz, 1H), 4.02 (bs, 2H), 3.17–2.87 (m,
7H), 2.85–2.73 (m, 2H), 2.44–2.39 (m, 1H), 1.67–1.56 (m, 3H), 1.52–
1.45 (m, 1H) 1.25 ppm (bs, 1H); 13C NMR (126 MHz, CDCl3): d=
168.8, 160.1, 158.1, 139.2, 139.2, 139.1, 135.9, 129.8, 129.1, 128.9,
128.8, 127.5, 123.8, 123.8, 111.4, 111.2, 56.5, 46.4, 46.0, 43.2, 42.8,
42.7, 40.9, 29.4, 29.3, 26.0, 24.2 ppm. 19F NMR (377 MHz, CDCl3): d=
@117.3 ppm; MS (ESI) m/z 432.1 [M+H]+ ; HRMS (ESI) found m/z
454.15748 [M+Na]+ , calcd for C22H26FN3O3SNa
+ m/z 545.15766;
½aA21D =@67.18 (CH2Cl2).
Compound 8 (25 mg, 85% isolated yield, off-white solid): 1H NMR
(500 MHz, CDCl3): d=7.81–7.76 (m, 1H), 7.73–7.68 (m, 2H), 7.54
(bs, 1H), 7.48–7.42 (m, 2H), 7.25–7.21 (m, 2H), 7.16 (dd, J=8.7,
1.7 Hz, 1H), 4.30 (t, J=7.5 Hz, 1H), 3.93–3.86 (m, 2H), 3.26–3.14 (m,
3H), 3.07 (dd, J=7.5, 1.8 Hz, 2H), 3.01 (t, J=5.9 Hz, 2H), 2.71–2.55
(m, 3H), 1.70–1.50 (m, 3H), 1.45–1.38 (m, 1H), 1.25 ppm (bs, 1H);
13C NMR (126 MHz, CDCl3): d=168.8, 159.6, 157.6, 138.9, 138.9,
138.7, 138.6, 133.3, 133.2, 132.3, 128.5, 128.4, 128.2, 128.0, 127.6,
127.5, 127.4, 126.2, 125.8, 123.2, 123.2, 110.9, 110.7, 56.2, 46.1, 45.8,
42.7, 42.2, 42.2, 40.4, 28.7, 28.7, 25.7, 23.9 ppm; 19F NMR (377 MHz,
CDCl3): d=@117.4 ppm; MS (ESI) m/z 482.1 [M+H]+ ; HRMS (ESI)
found m/z 482.19176 [M+H]+ , calcd for C26H29FN3O3S
+ m/z
482.19136; ½aA21D =@97.18 (CH2Cl2).
Compound 9 (18 mg, 75% isolated yield, off-white solid): 1H NMR
(400 MHz, CDCl3): d=7.43 (bs, 1H), 7.34 (dd, J=8.7, 1.7 Hz, 1H),
4.05 (s, 2H), 3.67 (s, 2H), 3.43 (t, J=6.8 Hz, 2H), 3.29 (t, J=6.8 Hz,
2H), 3.13 (t, J=5.9 Hz, 2H), 2.85 (t, J=5.9 Hz, 2H), 2.01–1.92 (m,
2H), 1.90–1.81 (m, 2H), 1.35 ppm (t, J=7.3 Hz, 1H); 13C NMR
(101 MHz, CDCl3): d=164.7, 160.3, 157.8, 139.1, 139.1, 137.8, 137.8,
129.0, 128.8, 123.5, 123.5, 111.3, 111.0, 46.2, 45.9, 45.4, 44.3, 42.8,
42.5, 42.4, k 29.0, 25.8, 24.1 ppm; 19F NMR (377 MHz, CDCl3): d=
@117.0 ppm; MS (ESI) m/z 342.0 [M+H]+ ; HRMS (ESI) found m/z
342.12923 [M+H]+ , calcd for C15H22N3O3S
+ m/z 342.12876.
Compound 10 (42 mg, 77% isolated yield, off-white solid): 1H NMR
(400 MHz, CDCl3): d=7.29–7.26 (m, 1H), 7.25–7.19 (m, 3H), 7.13
(dd, J=8.6, 1.8 Hz, 1H), 7.09–7.02 (m, 2H), 5.45 (bs, 1H), 4.03 (s,
2H), 3.77 (t, J=7.0 Hz, 1H), 3.12 (t, J=5.9 Hz, 2H), 2.95 (qd, J=
13.8, 7.0 Hz, 2H), 2.83–2.76 (m, 2H), 2.04–1.97 (m, 3H), 1.80–1.71
(m, 6H), 1.67–1.55 (m, 6H), 1.26 ppm (bs, 1H); 13C NMR (101 MHz,
CDCl3): d=168.5, 160.2, 157.7, 138.9, 138.8, 138.2, 138.1, 135.8,
129.3, 128.8, 128.7, 128.7, 128.5, 127.2, 123.5, 123.5, 111.1, 110.9,
58.6, 52.1, 42.7, 42.3, 42.3, 41.1, 39.4, 36.2, 29.3, 28.8, 28.8 ppm;
19F NMR (377 MHz, CDCl3): d=@116.6 ppm; MS (ESI) m/z 512.1
[M+H]+ ; HRMS (ESI) found m/z 512.23804 [M+H]+ , calcd for
C28H35FN3O3S
+ m/z 512.23831; ½aA21D =@19.18 (CH2Cl2).
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Compound 11 (39 mg, 81% isolated yield, white solid): 1H NMR
(400 MHz, CDCl3): d=7.35 (bs, J=1.6 Hz, 1H), 7.30–7.22 (m, 4H),
7.15–7.10 (m, 2H), 4.05 (s, 2H), 3.90 (dd, J=9.0, 6.1 Hz, 1H), 3.82–
3.64 (m, 3H), 3.13 (t, J=5.9 Hz, 2H), 3.07 (td, J=8.9, 6.2 Hz, 1H),
2.95–2.76 (m, 4H), 2.08–1.99 (m, 1H), 1.97–1.83 (m, 1H), 1.30–
1.22 ppm (m, 1H); 13C NMR (101 MHz, CDCl3): d=169.2, 160.1,
157.6, 139.1, 139.0, 138.9, 138.8, 135.7, 129.4, 128.7, 128.5, 128.5,
127.2, 123.4, 123.3, 111.0, 110.8, 53.7, 49.7, 47.6, 42.8, 42.4, 42.3,
40.2, 29.0, 28.9, 15.2 ppm; 19F NMR (377 MHz, CDCl3): d=
@117.2 ppm; MS (ESI) m/z 418.2 [M+H]+ ; HRMS (ESI) found m/z
418.16006 [M+H]+ , calcd for C21H25FN3O3S
+ m/z 418.15965; ½aA21D =
@87.08 (CH2Cl2).
Compound 12 (47 mg, 96% isolated yield, off-white solid): 1H NMR
(400 MHz, CDCl3): d=7.34–7.31 (m, 1H), 7.28–7.18 (m, 4H), 7.16–
7.09 (m, 2H), 4.41 (dd, J=7.8, 6.6 Hz, 1H), 4.02 (s, 2H), 3.36–3.26
(m, 1H), 3.26–3.17 (m, 1H), 3.10 (t, J=5.9 Hz, 2H), 3.04–2.72 (m,
6H), 1.51–1.07 (m, 6H), 0.99–0.80 ppm (m, 1H); 13C NMR (101 MHz,
CDCl3): d=168.3, 160.0, 157.6, 138.9, 138.8, 138.8, 138.7, 135.5,
129.6, 128.6, 128.5, 128.5, 127.2, 123.5, 123.5, 111.2, 111.0, 53.6,
46.3, 43.1, 42.8, 42.4, 42.3, 40.9, 29.0, 29.0, 25.6, 25.1, 24.0 ppm;
19F NMR (377 MHz, CDCl3): d=@117.2 ppm; MS (ESI) m/z 446.1
[M+H]+ ; HRMS (ESI) found m/z 446.19111 [M+H]+ , calcd for
C23H29FN3O3S
+ m/z 446.19136; ½aA21D =@92.08 (CH2Cl2).
Compound 13 (37 mg, 91% isolated yield, light-yellow solid):
1H NMR (400 MHz, CDCl3): d=7.34 (s, J=7.8 Hz, 1H), 7.30–7.20 (m,
4H), 7.16–7.09 (m, 2H), 4.39 (dd, J=9.4, 5.8 Hz, 1H), 4.03 (s, 2H),
3.47–3.28 (m, 3H), 3.28–3.07 (m, 4H), 3.04–2.64 (m, 7H), 1.25 ppm
(bs, 1H); 13C NMR (126 MHz, CDCl3): d=169.0, 159.8, 157.9, 139.0,
139.0, 138.9, 138.8, 135.4, 129.6, 129.0, 128.8, 128.7, 127.5, 123.4,
123.4, 111.1, 110.9, 66.2, 65.6, 53.3, 45.7, 42.8, 42.4, 42.4, 42.2, 41.0,
29.1, 29.0 ppm; 19F NMR (377 MHz, CDCl3): d=@117.3 ppm; MS
(ESI) m/z 448.1 [M+H]+ ; HRMS (ESI) found m/z 448.17145 [M+H]+
, calcd for C22H27FN3O4S
+ m/z 448.17063; ½aA21D =@86.28 (CH2Cl2).
Compound 14 (41 mg, 85% isolated yield, white solid): 1H NMR
(400 MHz, CDCl3): d=7.34–7.30 (m, 1H), 7.26–7.19 (m, 4H), 7.15–
7.09 (m, 2H), 4.34 (dd, J=7.7, 6.5 Hz, 1H), 4.01 (s, 2H), 3.31–3.20
(m, 1H), 3.13–3.00 (m, 3H), 2.99–2.82 (m, 4H), 2.78 (q, J=5.2 Hz,
2H), 1.25 (bs, 1H), 0.92 (t, J=7.1 Hz, 3H), 0.84 ppm (t, J=7.1 Hz,
3H); 13C NMR (126 MHz, CDCl3): d=169.5, 159.8, 157.9, 139.3,
139.2, 138.8, 138.7, 135.6, 129.5, 128.6, 128.5, 128.5, 127.2, 123.3,
123.3, 111.1, 110.9, 54.1, 42.8, 42.3, 42.3, 41.5, 40.9, 40.6, 29.0, 28.9,
13.7, 12.6 ppm; 19F NMR (377 MHz, CDCl3): d=@117.3 ppm; MS
(ESI) m/z 434.1 [M+H]+ ; HRMS (ESI) found m/z 434.19037 [M+H]+
, calcd for C22H29FN3O3S
+ m/z 434.19082; ½aA21D =@64.58 (CH2Cl2).
Compound 15 (38 mg, 95% isolated yield, off-white solid): 1H NMR
(400 MHz, CDCl3): d=7.31 (bs, 1H), 7.26–7.18 (m, 4H), 7.13–7.08
(m, 2H), 4.42 (dd, J=7.9, 6.8 Hz, 1H), 4.03 (s, 2H), 3.11 (t, J=5.9 Hz,
2H), 2.91 (d, J=8.4 Hz, 2H), 2.80 (q, J=5.7 Hz, 2H), 2.67 (s, 3H),
2.48 (s, 3H), 1.24 ppm (bs, 1H); 13C NMR (101 MHz, CDCl3): d=
170.3, 160.0, 157.6, 139.0, 139.0, 138.8, 138.7, 135.6, 129.3, 128.6,
128.5, 128.4, 127.2, 123.3, 123.3, 111.0, 110.7, 54.0, 42.8, 42.3, 42.3,
40.5, 36.5, 35.5, 28.9, 28.9 ppm; 19F NMR (377 MHz, CDCl3): d=
@117.3 ppm; MS (ESI) m/z 406.1 [M+H]+ ; HRMS (ESI) found m/z
406.16060 [M+H]+ , calcd for C20H25FN3O3S
+ m/z 406.16006; ½aA21D =
@91.18 (CH2Cl2).
Compound 16 (31 mg, 81% isolated yield, off-white solid): 1H NMR
(400 MHz, CDCl3): d=7.34 (bs, 1H), 7.30–7.19 (m, 4H), 7.12–7.07
(m, 2H), 4.04 (s, 1H), 3.23 (t, J=6.9 Hz, 1H), 3.11 (t, J=5.9 Hz, 1H),
2.86–2.75 (m, 4H), 2.06 (bs, 1H), 1.25 ppm (bs, 1H); 13C NMR
(101 MHz, CDCl3): d=160.3, 157.8, 138.9, 138.9, 138.7, 138.6, 137.6,
128.8, 128.8, 128.7, 128.7, 128.5, 126.9, 123.3, 123.3, 111.1, 110.8,
44.2, 42.7, 42.3, 42.3, 35.8, 28.9, 28.9 ppm; 19F NMR (377 MHz,
CDCl3): d=@116.9 ppm. MS (ESI) m/z 335.1 [M+H]+ ; HRMS (ESI)
found m/z 335.12305 [M+H]+ , calcd for C17H20FN2O2S
+ m/z
335.12295.
Compound 17 (88 mg, 88%, white solid): 1H NMR (500 MHz,
CDCl3): d=7.84–7.80 (m, 2H), 7.56–7.51 (m, 1H), 7.49–7.43 (m, 2H),
7.27–7.19 (m, 3H), 7.17–7.12 (m, 2H), 5.95–5.90 (d, J=9.5 Hz, 1H),
4.17–4.05 (td, J=9.5, 5.9 Hz, 1H), 3.14–3.06 (m, 1H), 3.03–2.89 (m,
3H), 2.87–2.80 (m, 1H), 2.32–2.24 (m, 1H), 1.57–1.36 ppm (m, 4H);
13C NMR (126 MHz, CDCl3): d=168.4, 139.9, 135.7, 132.6, 129.4,
128.8, 128.4, 127.2, 127.2, 56.0, 45.9, 45.5, 40.7, 25.6, 23.7 ppm; MS
(ESI) m/z 359.0 [M+H]+ ; HRMS (ESI) found m/z 381.12487 [M+
Na]+ , calcd for C19H22N2O3SNa
+ m/z 381.12433; ½aA21D =@125.88
(CH2Cl2).
Compound 18 (94 mg, 94% isolated yield, white solid): 1H NMR
(500 MHz, CDCl3): d=7.62 (dt, J=8.0, 1.7, 1.0 Hz, 1H), 7.51 (dt, J=
8.0, 2.5, 1.7 Hz, 1H), 7.45 (td, J=8.0, 5.2 Hz, 1H), 7.28–7.20 (m, 4H),
7.17–7.13 (m, 2H), 6.27 (d, J=9.7 Hz, 1H), 4.20 (ddd, J=9.7, 8.4,
6.7 Hz, 1H), 3.23–3.11 (m, 1H), 3.07–2.94 (m, 4H), 2.45–2.36 (m,
1H), 1.68–1.42 ppm (m, 4H); 13C NMR (126 MHz, CDCl3): d=168.3,
163.1, 161.1, 142.4, 142.3, 135.6, 130.7, 130.7, 129.4, 128.5, 127.2,
123.0, 122.9, 119.7, 119.6, 114.5, 114.3, 56.2, 46.0, 45.7, 40.5, 25.7,
23.8 ppm; 19F NMR (377 MHz, CDCl3): d=@109.8 ppm; MS (ESI) m/z
376.9 [M+H]+ ; HRMS (ESI) found m/z 399.11732 [M+Na]+ , calcd
for C19H21FN2O3SNa
+ m/z 399.11546; Optical rotation ½aA21D =
@116.48 (CH2Cl2).
Compound 19 (78 mg, 78% isolated yield, white solid): 1H NMR
(500 MHz, CDCl3): d=7.83–7.77 (m, 2H), 7.27–7.18 (m, 3H), 7.15–
7.06 (m, 4H), 6.15 (d, J=9.8 Hz, 1H), 4.19–4.09 (m, 1H), 3.18–3.08
(m, 1H), 3.05–2.89 (m, 4H), 2.44–2.35 (m, 1H), 1.63–1.51 (m, 3H),
1.50–1.41 ppm (m, 1H); 13C NMR (126 MHz, CDCl3): d=168.6, 166.0,
163.9, 136.2, 136.2, 135.6, 130.0, 129.9, 129.4, 128.5, 127.2, 116.0,
115.8, 56.0, 46.0, 45.7, 40.4, 25.6, 23.8 ppm; 19F NMR (377 MHz,
CDCl3): d=@105.4 ppm; MS (ESI) m/z 377.1 [M+H]+ ; HRMS (ESI)
found m/z 399.11607 [M+Na]+ , calcd for C19H21FN2O3SNa
+ m/z
399.11546; ½aA21D =@96.78 (CH2Cl2).
Compound 20 (88 mg, 99% isolated yield, white solid): 1H NMR
(500 MHz, CDCl3): d=7.32 (d, J=2.3 Hz, 1H), 7.30–7.19 (m, 4H),
7.17–7.11 (m, 2H), 6.89 (d, J=8.5 Hz, 1H), 5.81 (d, J=9.8 Hz, 1H),
4.33–4.21 (m, 4H), 4.13 (td, J=5.9, 9.55 Hz, 1H), 3.18–3.03 (m, 2H),
3.01–2.89 (m, 3H), 2.38–2.29 (m, 1H), 1.67–1.53 (m, 3H), 1.50–
1.39 ppm (m, 1H); 13C NMR (126 MHz, CDCl3): d=168.6, 147.2,
143.2, 135.8, 132.5, 129.4, 128.4, 127.1, 120.9, 117.5, 116.8, 64.5,
64.1, 56.0, 45.9, 45.6, 40.6, 25.7, 23.8 ppm; MS (ESI) m/z 417.0 [M+
H]+ ; HRMS (ESI) found m/z 439.13019 [M+Na]+ , calcd for
C21H24N2O5SNa
+ m/z 439.13036. ½aA21D =@106.48 (CH2Cl2).
Compound 21 (87 mg, 98% isolated yield, white solid): 1H NMR
(500 MHz, CDCl3): d=9.20 (s, 1H), 8.44 (dd, J=0.6, 1.90 Hz, 1H),
8.18 (dd, J=0.6, 8.6 Hz, 1H), 7.92 (dd, J=1.9, 8.6 Hz, 1H), 7.23–7.14
(m, 3H), 7.14–7.09 (m, 2H), 6.21 (bs, 1H), 4.19 (dd, J=6.4, 8.7 Hz,
1H), 3.10–2.93 (m, 3H), 2.93–2.77 (m, 2H), 2.42–2.33 (m, 1H), 1.51–
1.36 (m, 3H), 1.35–1.24 ppm (m, 1H); 13C NMR (126 MHz, CDCl3):
d=168.4, 157.9, 155.4, 137.4, 135.6, 133.8, 129.4, 128.4, 127.2,
125.0, 123.9, 122.0, 56.2, 45.9, 45.6, 40.5, 25.6, 23.7 ppm; MS (ESI)
m/z 416.1 [M+H]+ ; HRMS (ESI) found m/z 438.09165 [M+Na]+ ,
calcd for C20H21N3O3S2Na
+ m/z 438.09220. ½aA21D =@107.98 (CH2Cl2).
Compound 22 (89 mg, 97% isolated yield, white solid): 1H NMR
(500 MHz, CDCl3): d=7.62–7.55 (m, 2H), 7.25–7.17 (m, 3H), 7.15–
7.10 (m, 2H), 6.74 (d, J=8.3 Hz, 1H), 5.91 (d, J=9.9 Hz, 1H), 4.63 (t,
J=8.8 Hz, 2H), 4.16–4.06 (m, 1H), 3.29–3.09 (m, 3H), 3.05–2.88 (m,
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4H), 2.38–2.30 (m, 1H), 1.60–1.50 (m, 3H), 1.47–1.40 ppm (m, 1H);
13C NMR (126 MHz, CDCl3): d=168.8, 163.7, 135.8, 131.5, 129.4,
128.7, 128.4, 128.2, 127.1, 124.6, 108.8, 72.3, 55.9, 45.9, 45.6, 40.5,
29.0, 25.6, 23.8 ppm; MS (ESI) m/z 401.0 [M+H]+ ; HRMS (ESI)
found m/z 423.13553 [M+Na]+ , calcd for C21H24N2O4SNa
+ m/z
423.13553. ½aA21D =@124.28 (CH2Cl2).
Compound 23 (56 mg, 99% isolated yield, off-white solid): 1H NMR
(400 MHz, CDCl3): d=7.56–7.48 (m, 2H), 7.26–7.16 (m, 3H), 7.15–
7.04 (m, 3H), 4.13 (dd, J=8.9, 6.2 Hz, 1H), 4.07 (s, 2H), 3.21–3.06
(m, 3H), 3.06–2.71 (m, 7H), 2.40–2.26 (m, 1H), 1.64–1.48 (m, 3H),
1.50–1.36 (m, 1H), 1.23 ppm (bs, 1H); 13C NMR (101 MHz, CDCl3):
d=168.7, 140.1, 137.8, 135.8, 135.6, 129.4, 128.4, 128.0, 127.1,
126.8, 124.5, 56.0, 47.8, 45.9, 45.6, 43.2, 40.5, 28.8, 25.7, 23.8 ppm;
MS (ESI) m/z 414.1 [M+H]+ ; HRMS (ESI) found m/z 414.18487 [M+
H]+ , calcd for C22H28N3O3S
+ m/z 414.18514. ½aA21D =@96.98 (CH2Cl2).
Compound 24 (153 mg, 86% isolated yield, colorless oil): 1H NMR
(400 MHz, CDCl3): d=7.51–7.45 (m, 2H), 7.25–7.17 (m, 3H), 7.15–
7.08 (m, 3H), 5.77 (d, J=9.6 Hz, 1H), 4.08 (td, J=9.6, 5.9 Hz, 1H),
3.14–3.03 (m, 1H), 3.02–2.85 (m, 3H), 2.85–2.66 (m, 5H), 2.31–2.19
(m, 1H), 1.78 (p, J=3.3 Hz, 4H), 1.58–1.32 ppm (m, 4H); 13C NMR
(126 MHz, CDCl3): d=168.6, 142.6, 137.9, 136.7, 135.8, 129.4, 129.4,
128.4, 127.8, 127.1, 124.2, 55.9, 45.8, 45.4, 40.7, 29.5, 29.3, 25.6,
23.8, 22.7, 22.7 ppm; MS (ESI) m/z 413.1 [M+H]+ ; HRMS (ESI)
found m/z 435.17130 [M+Na]+ , calcd for C23H28O3N2SNa
+ m/z
435.17183. ½aA21D =@92.78 (CH2Cl2).
Compound 25 (32 mg, 79% isolated yield, light-yellow oil): 1H NMR
(400 MHz, CDCl3): d=7.30–7.23 (m, 2H), 7.19–7.09 (m, 3H), 7.09–
7.02 (m, 2H), 6.27 (d, J=8.5 Hz, 1H), 5.49 (d, J=9.8 Hz, 1H), 3.94
(td, J=9.8, 5.7 Hz, 1H), 3.25 (dd, J=6.1, 5.0 Hz, 2H), 3.06–2.87 (m,
3H), 2.87–2.51 (m, 4H), 2.20–2.06 (m, 1H), 1.85–1.75 (m, 2H), 1.51–
1.38 (m, 3H), 1.35–1.23 ppm (m, 1H); 13C NMR (101 MHz, CDCl3):
d=168.1, 147.4, 135.0, 128.4, 127.9, 127.3, 126.0, 125.9, 124.1,
119.0, 111.2, 54.8, 44.8, 44.5, 40.5, 39.7, 25.9, 24.6, 22.8, 20.1 ppm;
MS (ESI) m/z 414.0 [M+H]+ ; HRMS (ESI) found m/z 436.16680 [M+
Na]+ , calcd for C22H27N3O3SNa
+ m/z 436.16708; ½aA21D =@134.38
(CH2Cl2).
Compound 26 (62 mg, 95% isolated yield, off-white solid): 1H NMR
(500 MHz, CDCl3): d=7.53 (dd, J=8.0, 2.0 Hz, 1H), 7.46 (bs, 1H),
7.26–7.18 (m, 3H), 7.17–7.09 (m, 3H), 4.12 (dd, J=9.2, 6.0 Hz, 1H),
4.02 (q, J=16.2 Hz, 2H), 3.20–3.08 (m, 3H), 3.06–2.88 (m, 4H), 2.83
(t, J=6.0, 2H), 2.38–2.29 (m, 1H), 1.64–1.35 ppm (m, 4H); 13C NMR
(126 MHz, CDCl3): d=168.6, 140.2, 137.3, 136.5, 135.7, 129.7, 129.4,
128.4, 127.1, 125.2, 124.7, 56.0, 47.9, 45.9, 45.5, 43.2, 40.6, 29.2,
25.6, 23.8 ppm; MS (ESI) m/z 414.1 [M+H]+ ; HRMS (ESI) found m/z
414.18545 [M+H]+ , calcd for C22H28N3O3S
+ m/z 414.18514; ½aA21D =
@107.98 (CH2Cl2).
Compound 27 (35 mg, 87% isolated yield, light-yellow solid):
1H NMR (400 MHz, CDCl3): d=7.56 (dd, J=8.0, 1.8 Hz, 1H), 7.51–
7.46 (m, 1H), 7.42 (dd, J=9.4, 1.8 Hz, 1H), 7.26–7.17 (m, 3H), 7.16–
7.08 (m, 2H), 4.19 (dd, J=8.5, 6.6 Hz, 1H), 3.94 (s, 2H), 3.14 (dd, J=
13.0, 6.1 Hz, 1H), 3.10–2.99 (m, 2H), 3.00–2.84 (m, 2H), 2.50–2.36
(m, 1H), 1.71–1.54 (m, 3H), 1.54–1.41 ppm (m, 1H); 13C NMR
(126 MHz, CDCl3): d=168.4, 161.0, 159.0, 140.5, 140.5, 135.6, 135.2,
135.1, 129.5, 129.5, 129.4, 128.5, 127.2, 123.1, 123.0, 114.3, 114.1,
56.2, 46.1, 45.7, 40.5, 40.0, 39.9, 25.7, 23.8 ppm; 19F NMR (377 MHz,
CDCl3): d=@116.5 ppm; MS (ESI) m/z 406.1 [M+H]+ ; HRMS (ESI)
found m/z 406.16057 [M+H]+ , calcd for C20H25FN3O3S
+ m/z
406.16006; ½aA21D =@82.28 (CH2Cl2).
Compound 28 (69 mg, 75% isolated yield, white solid): 1H NMR
(500 MHz, [D6]DMSO): d=8.39 (s, 1H), 8.14 (s, 1H), 7.95 (d, J=
8.5 Hz, 1H), 7.71 (d, J=8.5 Hz, 2H), 7.58 (s, 1H), 7.28–7.09 (m, 4H),
4.10 (t, J=7.6 Hz, 1H), 3.24–3.15 (m, 1H), 2.92 (dt, J=6.9, 11.5 Hz,
1H), 2.88–2.66 (m, 4H), 1.71–1.60 (m, 1H), 1.52–1.45 ppm (m, 3H);
13C NMR (126 MHz, [D6]DMSO): d=168.0, 167.1, 143.5, 137.8, 137.0,
129.7, 128.6, 128.3, 127.1, 126.7, 56.1, 46.0, 45.6, 38.6, 25.2,
23.8 ppm; MS (ESI) m/z 402.0 [M+H]+ ; HRMS (ESI) found m/z
424.13147 [M+Na]+ , calcd for C20H23N3O4SNa
+ m/z 424.13070;
½aA21D =@91.78 (CH2Cl2).
Compound 29 (20 mg, 99% isolated yield, TFA salt, white solid):
1H NMR (500 MHz, CD3OD): d=7.67 (d, J=1.5 Hz, 1H), 7.57 (dd, J=
9.2, 1.6 Hz, 1H), 4.47 (s, 2H), 3.57 (t, J=6.3 Hz, 2H), 3.23 ppm (t, J=
6.3 Hz, 2H); 13C NMR (126 MHz, CD3OD): d=160.0, 158.0, 145.1,
145.0, 135.4, 135.3, 122.0, 122.0, 120.3, 120.1, 110.9, 110.7, 40.7,
39.3, 39.2, 24.5, 24.5 ppm; 19F NMR (377 MHz, MeOD): d=@77.0
(CF3COO
@), @118.1 ppm; MS (ESI) m/z 231.1 [M+H]+ ; HRMS (ESI)
found m/z 231.06035 [M+H]+ , calcd for C9H12FN2O2S
+ m/z
231.05922.
Compound 30 (943 mg, 80% isolated yield, yellow solid): 1H NMR
(400 MHz, CDCl3): d=7.32–7.26 (m, 2H), 7.25–7.18 (m, 3H), 3.71 (t,
J=7.2 Hz, 1H), 3.52–3.43 (m, 1H), 3.42–3.29 (m, 2H), 2.95 (dd, J=
13.1, 7.2 Hz, 1H), 2.84–2.75 (m, 2H), 1.86–1.60 (m, 6H). 13C NMR
(126 MHz, CDCl3): d=173.1, 137.9, 129.3, 128.4, 126.7, 55.2, 46.0,
45.8, 43.0, 25.9, 24.0 ppm. MS (ESI) m/z 219.0 [M+H]+ ; HRMS (ESI)
found m/z 241.13149 [M+Na]+ , calcd for C13H18N2ONa
+ m/z
241.13168.
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